Literature DB >> 15144872

Clenbuterol retards loss of motor function in motor neuron degeneration mice.

Richard J Zeman1, Hong Peng, Joseph D Etlinger.   

Abstract

Motor neuron degeneration (mnd) mice exhibit lysosomal accumulation of lipofuscin-like material that is associated with progressive loss of motor function and strength. Motor dysfunction scores at 8.5-9 months of age were highly correlated with the occurrence of abnormal spinal motor neurons with eccentric nuclei, although the total numbers of motor neurons were not significantly reduced. Nuclear eccentricity is a characteristic of the axon reaction that results from injury and subsequent compensatory axonal sprouting indicating axonal/synaptic dysfunction in mnd motor neurons. Treatment with clenbuterol, a beta(2)-adrenoceptor agonist that can enhance regeneration of motor neuron axons, opposed the development of motor deficits in parallel with a reduced proportion of motor neurons with eccentric nuclei consistent with improved synaptic function. Clenbuterol also opposed decreases in grip strength and muscle mass suggesting beta(2)-agonist treatment as a potential therapeutic modality for lipofuscinoses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15144872     DOI: 10.1016/j.expneurol.2004.03.006

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  14 in total

1.  A mixed breed dog with neuronal ceroid lipofuscinosis is homozygous for a CLN5 nonsense mutation previously identified in Border Collies and Australian Cattle Dogs.

Authors:  Natalie A Villani; Garrett Bullock; Jennifer R Michaels; Osamu Yamato; Dennis P O'Brien; Tendai Mhlanga-Mutangadura; Gary S Johnson; Martin L Katz
Journal:  Mol Genet Metab       Date:  2019-04-17       Impact factor: 4.797

Review 2.  Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.

Authors:  R Kohan; I A Cismondi; A M Oller-Ramirez; N Guelbert; Tapia V Anzolini; G Alonso; S E Mole; Dodelson R de Kremer; Noher I de Halac
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

3.  Partial functional recovery after complete spinal cord transection by combined chondroitinase and clenbuterol treatment.

Authors:  Fusheng Bai; Hong Peng; Joseph D Etlinger; Richard J Zeman
Journal:  Pflugers Arch       Date:  2010-06-16       Impact factor: 3.657

Review 4.  cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration.

Authors:  Rebecca Berdeaux; Randi Stewart
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-21       Impact factor: 4.310

5.  Progesterone effects on neuronal ultrastructure and expression of microtubule-associated protein 2 (MAP2) in rats with acute spinal cord injury.

Authors:  Susana L González; Juan José López-Costa; Florencia Labombarda; Maria Claudia González Deniselle; Rachida Guennoun; Michael Schumacher; Alejandro F De Nicola
Journal:  Cell Mol Neurobiol       Date:  2008-06-27       Impact factor: 5.046

Review 6.  Progress in the Development of Small Molecule Therapeutics for the Treatment of Neuronal Ceroid Lipofuscinoses (NCLs).

Authors:  Nihar Kinarivala; Paul C Trippier
Journal:  J Med Chem       Date:  2015-11-24       Impact factor: 7.446

7.  Effects of clenbuterol on contractility and Ca2+ homeostasis of isolated rat ventricular myocytes.

Authors:  U Siedlecka; M Arora; T Kolettis; G K R Soppa; J Lee; M A Stagg; S E Harding; M H Yacoub; C M N Terracciano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-09-05       Impact factor: 4.733

Review 8.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

9.  Clenbuterol-sensitive delayed outward potassium currents in a cell model of spinal and bulbar muscular atrophy.

Authors:  Vladimir A Martínez-Rojas; Daniele Arosio; Maria Pennuto; Carlo Musio
Journal:  Pflugers Arch       Date:  2021-05-22       Impact factor: 3.657

10.  AAV9 Gene Therapy Increases Lifespan and Treats Pathological and Behavioral Abnormalities in a Mouse Model of CLN8-Batten Disease.

Authors:  Tyler B Johnson; Katherine A White; Jon J Brudvig; Jacob T Cain; Logan Langin; Melissa A Pratt; Clarissa D Booth; Derek J Timm; Samantha S Davis; Brandon Meyerink; Shibi Likhite; Kathrin Meyer; Jill M Weimer
Journal:  Mol Ther       Date:  2020-09-24       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.